The prognostic role of Ki-67/MIB-1 in cervical cancer: A systematic review with meta-analysis

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 882-889

  Pan, Denghua ^a   Wei, Kanglai ^a   Ling, Yanxin ^a   Su, Shitao ^a   Zhu, Meilin ^a   Chen, Gang ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Ki 67 antigen; Meta analysis; Prognosis; Uterine cervical neoplasms

Indexed keywords

MONOCLONAL ANTIBODY KI 67; TUMOR MARKER; KI 67 ANTIGEN;

ARTICLE; CANCER PROGNOSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FOLLOW UP; HAZARD RATIO; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; FEMALE; METABOLISM; PROGNOSIS; PUBLISHING; UTERINE CERVIX TUMOR;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KI-67 ANTIGEN; PROGNOSIS; PUBLICATION BIAS; UTERINE CERVICAL NEOPLASMS;

EID: 84925650270     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.892807     Document Type: Article

References (40)

1. Kesic V, Poljak M, Rogovskaya S: Cervical cancer burden and prevention activities in Europe. Cancer Epidemiol Biomarker, 2012, 21(9): 1423-1433
2. Eskander RN, Tewari KS: Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. J Gynecol Oncol, 2014, 25(3): 249-259
3. Key G, Becker MH, Baron B et al: New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Inves, 1993; 68(6): 629-636
4. de Azambuja E, Cardoso F, de Castro G Jr et al: Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer, 2007; 96(10): 1504-1513
5. Martin B, Paesmans M, Mascaux C et al: Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer, 2004; 91(12): 2018-2025
6. Kritpracha K, Hanprasertpong J, Chandeying V et al: Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining. J Obstet Gynaecol Res, 2005; 31(3): 268-276
7. Vasilescu F, Ceausu M, Tanase C et al: P53, p63 and Ki-67 assessment in HPV-induced cervical neoplasia. Rom J Morphol Embryol, 2009; 50(3): 357-361
8. Van de Putte G, Kristensen GB, Lie AK et al: Cyclins and proliferation markers in early squamous cervical carcinoma. Gynecol Oncol, 2004; 92(1): 40-46
9. Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 1998; 17(24): 2815-2834
10. Yusuf S, Peto R, Lewis J et al: Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis, 1985; 27(5): 335-371
11. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 1959; 22(4): 719-748
12. Avall-Lundqvist EH, Silfversward C, Aspenblad U et al: The impact of tumour angiogenesis, p53 overexpression and proliferative activity (MIB-1) on survival in squamous cervical carcinoma. Eur J Cancer, 1997; 33(11): 1799-1804
13. Bahnassy AA, Zekri AR, Alam El-Din HM et a: The role of cyclins and cyclins inhibitors in the multistep process of HPV-associated cervical carcinoma. J Egypt Natl Canc Inst, 2006; 18(4): 292-302
14. Bahnassy AA, Zekri AR, Saleh M et al: The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma. BMC Clin Pathol, 2007; 7: 4
15. Cattoretti G, Becker MH, Key G et al: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol, 1992; 168(4): 357-363
16. Dellas A, Schultheiss E, Almendral AC et al: Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. Int J Cancer, 1997; 74(4): 421-425
17. Graflund M, Sorbe B, Karlsson M: MIB-1, p53, bcl-2, and WAF-1 expression in pelvic lymph nodes and primary tumors in early stage cervical carcinomas: correlation with clinical outcome. Int J Oncol, 2002; 20(5): 1041-1047
18. Ho DM, Hsu CY, Chiang H: MIB-1 labeling index as a prognostic indicator for survival in patients with FIGO stage IB squamous cell carcinoma of the cervix. Gynecol Oncol, 2000; 76(1): 97-102
19. Klimek M, Kruczak A, Rys J et al: Clinico-morphological parameters affecting survival of patients with advanced cervical cancer. Pol J Pathol, 2011; 62(4): 250-256
20. Morimura Y, Yanagida K, Hashimoto T et al: Evaluation of immunostaining for MIB1 and nm23 products in uterine cervical adenocarcinoma. Tohoku J Exp Med, 1998; 185(3): 185-197
21. Nakano T, Oka K: Differential values of Ki-67 index and mitotic index of proliferating cell population. An assessment of cell cycle and prognosis in radiation therapy for cervical cancer. Cancer, 1993; 72(8): 2401-2408
22. Oka K, Arai T: MIB1 growth fraction is not related to prognosis in cervical squamous cell carcinoma treated with radiotherapy. Int J Gynecol Pathol, 1996; 15(1): 23-27
23. Oka K, Suzuki Y, Nakano T: High growth fraction at 9 grays of radiotherapy is associated with a good prognosis for patients with cervical squamous cell carcinoma. Cancer, 2000; 89(7): 1526-1531
24. Shiohara S, Shiozawa T, Miyamoto T et al: Expression of cyclins, p53, and Ki-67 in cervical squamous cell carcinomas: overexpression of cyclin A is a poor prognostic factor in stage Ib and II disease. Virchows Arch, 2005; 446(6): 626-633
25. Sultana H, Kigawa J, Kanamori Y et al: Chemosensitivity and p53-Bax pathway- mediated apoptosis in patients with uterine cervical cancer. Ann Oncol, 2003; 14(2): 214-219
26. Suzuki M, Tsukagoshi S, Saga Y et al: Assessment of proliferation index with MIB-1 as a prognostic factor in radiation therapy for cervical cancer. Gynecol Oncol, 2000; 79(2): 300-304
27. Yang M, Liu YD, Wang YY et al: Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics. Tumour Biol, 2014; 35(2): 929-934
28. Zhang T, Zhao C, Chen D, Zhou Z: Overexpression of AQP5 in cervical cancer: correlation with clinicopathological features and prognosis. Med Oncol, 2012; 29(3): 1998-2004
29. Zhang T, Zhao C, Luo L et al: The expression of Mcl-1 in human cervical cancer and its clinical significance. Med Oncol, 2012; 29(3): 1985-1991
30. Costa S, Terzano P, Santini D et al: Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis, and proliferation as determinants of response to therapy and disease outcome. Am J Clin Pathol, 2001; 116(5): 729-737
31. Tian H, Qian GW, Li W et al: A critical role of Sp1 transcription factor in regulating he human Ki-67 gene expression. Tumour Biol, 2011; 32(2): 273-283
32. Chen M, Huang J, Zhu Z et al: Systematic review and meta-analysis of tumorbiomarkers in predicting prognosis in esophageal cancer. BMC Cancer, 2013; 13: 539
33. Scagliotti GV, Micela M, Gubetta L et al: Prognostic significance of Ki67 labelling in resected non small cell lung cancer. Eur J Cancer, 1993; 29A(3): 363-365
34. Shrestha ML, Miyake H, Kikutsuji T, Tashiro S: Prognostic significance of Ki-67 and p53 antigen expression in carcinomas of bile duct and gallbladder. J Med Invest, 1998; 45(1-4): 95-102
35. Cole DJ, Brown DC, Crossley E et al: Carcinoma of the cervix uteri: an assessmentof the relationship of tumour proliferation to prognosis. Br J Cancer, 1992; 65(5): 783-785
36. Lindboe CF, Torp SH: Comparison of Ki-67 equivalent antibodies. J Clin Pathol, 2002; 55(6): 467-471
37. Lindboe CF, von der Ohe G, Torp SH: Determination of proliferation index in neoplasms using different Ki-67 equivalent antibodies. APMIS, 2003; 111(5): 567-570
38. Altman DG, Lausen B, Sauerbrei W, Schumacher M: Dangers of using “optimal”cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst, 1994; 86(11): 829-835
39. Spyratos F, Ferrero-Pous M, Trassard M et al: Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoffvalue. Cancer, 2002; 94(8): 2151-2159
40. Walts AE, Ines D, Marchevsky AM: Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors. Mod Pathol, 2012; 25(9): 1258-1264